146 related articles for article (PubMed ID: 31033338)
1. Proton pump inhibitors versus
Brilhante RS; da Rocha MG; de Oliveira JS; España JD; Pereira VS; Scm Castelo-Branco D; A Pereira-Neto W; Sidrim JJ; A Cordeiro R; Rocha MF
Future Microbiol; 2019 Apr; 14():489-497. PubMed ID: 31033338
[No Abstract] [Full Text] [Related]
2. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
4. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Akter S; Hassan MR; Shahriar M; Akter N; Abbas MG; Bhuiyan MA
Alzheimers Res Ther; 2015 Dec; 7():79. PubMed ID: 26714488
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
Pasupuleti B; Gone V; Baddam R; Venisetty RK; Prasad OP
Curr Drug Metab; 2020; 21(2):126-131. PubMed ID: 32067615
[TBL] [Abstract][Full Text] [Related]
9. Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Terranova C; Petrella C; Improta G; Severini C; Signore F; Damiani P; Plotti F; Scarpignato C; Angioli R
Eur J Pharm Sci; 2014 Feb; 52():125-31. PubMed ID: 24215738
[TBL] [Abstract][Full Text] [Related]
10. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Escoffier J; Arnaud B; Kaba M; Hograindleur JP; Le Blévec E; Martinez G; Stévant I; Ray PF; Arnoult C; Nef S
Andrology; 2020 Nov; 8(6):1795-1804. PubMed ID: 32609951
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments.
Dahabiyeh LA; Abu-Rish EY; Taha MO
Pharmacol Rep; 2020 Apr; 72(2):435-442. PubMed ID: 32048247
[TBL] [Abstract][Full Text] [Related]
12. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
13. Restoration of acid secretion following treatment with proton pump inhibitors.
Shin JM; Sachs G
Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E; Toumi H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142643
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
17. Qualimetric analysis of proton pump inhibitors in Ukraine.
Makarenko OV; Karimova MM; Masheiko AM; Onul NM
Wiad Lek; 2019; 72(9 cz 2):1769-1773. PubMed ID: 31622264
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Zeng C; Neogi T; Chan AT; Wei J; Misra D; Lu N; Choi HK; Lei G; Zhang Y
Osteoarthritis Cartilage; 2022 Apr; 30(4):559-569. PubMed ID: 35031493
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
Chen CH; Yang JC; Uang YS; Lin CJ
Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
[TBL] [Abstract][Full Text] [Related]
20. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
